FDA Forms New Board for Drug Exclusivity
The US Food and Drug Administration has formed a dedicated board to oversee and advise on drug exclusivity determinations. The new body aims to improve clarity and consistency regarding market protection decisions for pharmaceutical products.
The United States Food and Drug Administration established a new review board on Friday afternoon to oversee drug exclusivity determinations. The initiative aims to improve clarity and consistency across regulatory decisions. Drug exclusivity rewards pharmaceutical innovation by granting newly approved treatments a period of market protection before lower-cost generic competitors launch.
